Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

December 8, 2022

https://www.globenewswire.com/news-release/2022/12/08/2570052/0/en/Pharvaris-Announces-Positive-Top-line-Phase-2-Data-from-RAPIDe-1-Study-of-PHVS416-for-the-On-Demand-Treatment-of-HAE-Attacks.html

ZUG, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings.

Read more at globenewswire.com

Related news for (PHVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.